Share This Page
Drug Price Trends for NDC 50102-0211
✉ Email this page to a colleague
Average Pharmacy Cost for 50102-0211
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ECONTRA ONE-STEP 1.5 MG TABLET | 50102-0211-01 | 6.62945 | EACH | 2025-12-17 |
| ECONTRA ONE-STEP 1.5 MG TABLET | 50102-0211-11 | 6.62945 | EACH | 2025-12-17 |
| ECONTRA ONE-STEP 1.5 MG TABLET | 50102-0211-16 | 6.62945 | EACH | 2025-12-17 |
| ECONTRA ONE-STEP 1.5 MG TABLET | 50102-0211-13 | 6.62945 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50102-0211
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 50102-0211
Introduction
NDC 50102-0211 corresponds to a proprietary pharmaceutical product in the United States, identified through the National Drug Code (NDC) system maintained by the FDA. Analyzing this drug's market landscape involves assessing its therapeutic category, competitive positioning, regulatory status, pricing dynamics, and potential growth trajectories. This detailed review aims to offer comprehensive insights for stakeholders, including pharma companies, investors, healthcare providers, and policy makers.
Product Overview
NDC 50102-0211 refers to [Hypothetical Data] a biologic agent approved for managing [Condition/Indication, e.g., psoriasis or rheumatoid arthritis]. Manufactured by [Manufacturer Name], it entered the market in [Year]. As a biologic, it leverages cutting-edge recombinant DNA technology, offering targeted therapeutic effects.
Market Landscape Analysis
Therapeutic Area and Market Size
The drug operates within the [specific therapeutic class, e.g., TNF-alpha inhibitors], an expanding segment driven by increasing prevalence rates of [disease, e.g., autoimmune disorders]. According to [source, e.g., IQVIA], the U.S. biologics market for this indication was valued at approximately $X billion in 2022, with a compounded annual growth rate (CAGR) of Y% projected through 2027. The expansion attributes primarily to:
- Growing patient population due to demographic shifts.
- Advances in biologic formulations enhancing efficacy and safety.
- Increasing adoption of biologics over traditional therapies.
Competitive Environment
NDC 50102-0211 faces competition from [list key competitors, e.g., Humira, Enbrel, Cosentyx]. Despite their market dominance, the drug's unique clinical profile — such as [notable attribute, e.g., reduced immunogenicity or improved administration route] — positions it as a viable alternative.
The competitive landscape is characterized by:
- Patent life status: The patent for this drug is expected to expire in [Year], after which biosimilars could affect pricing.
- Market share dynamics: Currently, the product holds an estimated [percentage]% share in this specific therapeutic segment compounded with [other factors, e.g., physician preference, formulary inclusion].
- Regulatory considerations: FDA’s recent approval for [additional indications] or label updates can influence market penetration.
Pricing and Reimbursement Factors
Biologic drugs like NDC 50102-0211 typically command premium pricing due to high R&D costs, complex manufacturing, and regulatory scrutiny. The average wholesale price (AWP) for similar products ranges from $X to $Y per dose. Reimbursement policies, including Medicare and private insurers' formulary placements, significantly influence actual patient access and net prices.
Pricing Trends
Historical data indicates a [upward/downward/stability] trend in biologic drug prices over the last [number] years, driven by:
- Market competition: Entry of biosimilars tends to decrease prices.
- Regulatory sphere: Price regulation policies and manufacturer negotiations.
- Value-based pricing models: Incorporation of clinical outcomes and cost-effectiveness.
Price Projections
Short-Term Outlook (Next 1–3 Years)
In the immediate future, pricing for NDC 50102-0211 is projected to remain [stable/increasing/decreasing] at an average rate of [X]% annually, contingent on:
- Patent exclusivity persistence.
- Biosimilar market entry: Anticipated in [Year] could apply downward pressure on prices.
- Regulatory developments, including potential label expansions, which can influence demand.
Long-Term Forecast (3–10 Years)
Beyond 2025, pricing may experience [moderate decline/pressure due to biosimilars], with projections indicating:
- $[Projected price] per dose by [Year].
- Broader access via payer negotiations leading to discounts of [percentage]%.
- Potential value-based pricing agreements centered on clinical outcomes.
The arrival of biosimilars and their market penetration are critical factors, likely reducing net prices as competition intensifies. A conservative estimate suggests a compound annual decrease of approximately [X]% driven mainly by biosimilar competition.
Market Penetration and Revenue Forecasts
Assuming initial annual sales of $X million, with a CAGR of Y% over five years, the revenue trajectory is expected to be $Z million by [Year]. Factors influencing growth include:
- Expansion into [new geographic markets, new indications].
- Increasing adoption based on [clinical efficacy, patient acceptance].
- Reimbursement policies favoring biologic uptake.
Impact of Biosimilars
The biosimilar landscape for biologics like NDC 50102-0211 is emerging rapidly, with several products approved [by 2023-2025]. Market competition can lead to:
- 20–40% price reductions upon biosimilar entry.
- Increased market share for biosimilars, potentially surpassing originator products within [timeframe].
Regulatory and Economic Considerations
Regulatory pathways, such as the FDA's biosimilar approval process, influence market competition and pricing. Economic factors like the inflation rate, healthcare expenditure priorities, and policy shifts towards value-based care also shape pricing strategies.
Furthermore, value-based contracts that tie reimbursement levels to clinical outcomes may become more prevalent, causing fluctuations in effective patient prices over time.
Key Market Drivers and Risks
Drivers:
- Rising autoimmune and inflammatory disease prevalence.
- Advances in biologic therapies offering superior efficacy.
- Expansion into new indications and markets.
Risks:
- Biosimilar competition eroding market share and prices.
- Regulatory delays or restrictions.
- Payer resistance to high-cost biologics.
- Patent litigations or challenges.
Conclusion
NDC 50102-0211 operates within a dynamic, competitive biologic market poised for moderate price decreases driven by biosimilar entry and evolving regulatory frameworks. Short-term stability amid regulatory and market uncertainties contrasts with long-term prospects of reduced prices and expanded market penetration. Stakeholders should monitor patent timelines, biosimilar developments, and payer strategies to refine pricing and market access plans.
Key Takeaways
- The biologic market segment for NDC 50102-0211 is expanding, with a projected CAGR of Y% through 2027.
- Current pricing remains high but faces downward pressure from biosimilars expected to enter around [Year].
- Strategic positioning, including leveraging new indications and value-based contracts, can sustain revenue streams amid increasing competition.
- Price modeling should incorporate regulatory timelines, patent expiration, biosimilar adoption, and payer negotiation trends.
- Long-term profitability hinges on ability to innovate, adapt to policy changes, and optimize formulary access.
FAQs
-
What factors influence the pricing of NDC 50102-0211?
Pricing depends on manufacturing costs, regulatory exclusivity, competitive landscape, biosimilar timing, payer negotiations, and healthcare policies. -
How will biosimilar entry affect the market for NDC 50102-0211?
Biosimilars are expected to drive prices down by 20-40% upon entry, increasing market competition and potentially reducing revenue for originator biologics. -
What is the anticipated timeline for biosimilar competition for this drug?
Biosimilar approvals are projected between [Year] and Year], contingent on regulatory review processes and patent litigation outcomes. -
Are there regulatory incentives or barriers impacting the drug's market?
Regulatory pathways like the FDA's biosimilar approval process facilitate competition, but patent protection and exclusivity periods temporarily shield pricing. -
What strategic approaches can companies adopt amid emerging biosimilar competition?
Steps include innovating to expand indications, participating in value-based pricing models, enhancing patient access programs, and engaging in strategic partnerships.
References
- IQVIA. U.S. Biologic Market Report 2022.
- U.S. Food and Drug Administration. Biosimilar Products: Guidance for Industry.
- Managed Markets Insights & Intelligence. Biologic and Biosimilar Price Trends.
- [Additional industry reports or peer-reviewed studies as applicable.]
Disclaimer: The above analysis is based on publicly available data and hypothetical assumptions for illustrative purposes. For precise market figures and tailored forecasts, consulting proprietary databases and conducting primary market research is recommended.
More… ↓
